|

Empagliflozin 25 MG Clinical Trials

10 actively recruiting trials across 1 location

No change since May 2026

Also known as: Jardiance, Jardiance (DIN: 02443945), Jardiance 25 MG, Jardiance® 25mg Film-Coated Tablets

Pipeline

Early 1: 2Phase 1: 3Phase 4: 3

Top Sponsors

The University of Texas Health Science Center at San Antonio4
National Taiwan University Hospital2
University Hospital, Basel, Switzerland1
Medanta, The Medicity, India1
Karolinska Institutet1

Indications

Diabetes7
Type 2 Diabetes5
Heart Disease3
Heart Failure With Preserved Ejection Fraction2
End Stage Renal Disease on Dialysis2

Other6 trials

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

N/A

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Phase 4

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

N/A

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Phase 4

Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

Phase 4

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

Phase 1

San Antonio, Texas4 trials

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

University of Texas Health Science Center at San Antonio

Early 1

SGLT2i, Hepatic Glucose Production, and SNS

Texas Diabetes Institute/UH

Early 1

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Texas Diabetes Institute/UH

Phase 1

SGLTi, Hepatic Glucose Production and Ketogenesis

Texas Diabetes Institute/UH

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.